Trial: 202003168

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with
Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib
vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with
Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase

III

Principal Investigator

Morgensztern, Daniel

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov